scispace - formally typeset
B

Bruce M. Spiegelman

Researcher at Harvard University

Publications -  443
Citations -  172265

Bruce M. Spiegelman is an academic researcher from Harvard University. The author has contributed to research in topics: Adipose tissue & Transcription factor. The author has an hindex of 179, co-authored 434 publications receiving 158009 citations. Previous affiliations of Bruce M. Spiegelman include University of California, San Francisco & Vassar College.

Papers
More filters
Journal ArticleDOI

Retrograde influence of muscle fibers on their innervation revealed by a novel marker for slow motoneurons

TL;DR: Overexpression of the transcriptional co-regulator PGC1α in muscle fibers leads to an increased frequency of SV2A-positive motor nerve terminals, indicating a fiber type-specific retrograde influence of muscle fibers on their innervation.
Patent

Methods and pharmaceutical compositions for inhibiting tumor cell growth

TL;DR: In this article, the authors showed that PPARγ activation plays a key role in inducing growth arrest and differentiation of certain actively proliferating cells, and they also showed that administration of TZDs is effective both in vitro and in vivo at inhibiting the pro proliferation of such cells.
Journal ArticleDOI

γδ T cells and adipocyte IL-17RC control fat innervation and thermogenesis.

TL;DR: These findings demonstrate coordination between T cells and parenchymal cells to regulate sympathetic innervation and control tolerance to cold by activating adipocyte IL-17RC and promoting sympatheticinnervation of thermogenic adipose tissue in mice.
Journal ArticleDOI

Adipsin, the adipocyte serine protease: gene structure and control of expression by tumor necrosis factor.

TL;DR: The results show that adipsin is a novel serine protease gene whose expression is regulated by a macrophage-derived factor which modulates expression of other adipocyte-specific RNAs.
Journal ArticleDOI

A novel therapeutic approach to treating obesity through modulation of TGFβ signaling.

TL;DR: The data demonstrate that novel therapeutic ActRIIB-Fc improves obesity and obesity-linked metabolic disease by both increasing skeletal muscle mass and by inducing a gene program of thermogenesis in the white adipose tissues.